Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

FEBRUARY 21, 2018

Another successful year for Pharmatest

Year 2017 was again the most successful year in the history of Pharmatest, beating clearly the previous sales records from 2016. The sales of Pharmatest increased by 50% in 2017 compared with 2016, and the growth is expected to continue further during 2018 and beyond.

Pharmatest Services (Pharmatest) is a CRO that offers preclinical efficacy services in the fields of oncology and skeletal diseases. In oncology Pharmatest has been a pioneer in offering bone metastasis models since 2005, and is today the global leader in the field.

Pharmatest reached its all-time records in sales and sales growth in 2017. As a result of the strong sales growth, Pharmatest has received three years in a row certification of the highest Dun & Bradstreet Credit Worthiness classification, which is given each year to only 4% of all companies in Finland.

The growth is a result of several years of successful marketing and R&D activities that have produced reliable and predictive high quality preclinical efficacy models. Pharmatest’s current R&D activities are concentrated in development of bone metastasis models for immuno-oncology and radiotherapy applications, in which there is a very strong growth potential for the business of Pharmatest.

Jussi Halleen, CEO of Pharmatest comments: “I am very pleased about the strong growth of our business that we expect to continue also in the future. The novel bone metastasis models that we are currently developing for immuno-oncology and radiotherapy applications will form a strong backbone for the future growth of our business.”